Unexpected Response to Nab-Paclitaxel in Poor Performance Status Lung Adenocarcinoma With a Unique 'Pan-Positive'...

Patients with advanced non-small cell lung cancer and poor performance status (PS) are often excluded from chemotherapy. We present a 63-year-old male with metastatic, poorly differentiated lung adenocarcinoma, ECOG PS 3, and an exceptionally broad, markedly elevated panel of tumour markers. He tolerated initial single-agent nab-paclitaxel with significant clinical and serological improvement, allowing treatment escalation. This report details the dynamic, often discordant, changes in this marker panel throughout treatment. This case suggests that carefully selected patients with poor PS may derive clinical benefit from chemotherapy and that monitoring a marker profile may provide insights into mechanisms of therapeutic efficacy and resistance.